A constipation medication slows kidney decline by fixing the gut
In the quiet corridors of Tohoku University, Japanese researchers have found an unexpected bridge between two seemingly unrelated conditions — constipation and kidney decline. By asking whether treating one might ease the other, they have uncovered a therapeutic pathway through the gut's microbial world and the cellular machinery of mitochondria, offering millions of chronic kidney disease patients something medicine has long withheld from them: a means of slowing what has always felt inevitable.
- Chronic kidney disease silently strips millions of their independence, offering no approved drugs that can restore what is lost — only dialysis waiting at the end of the road.
- A Phase II trial across nine Japanese medical centers found that lubiprostone, a common constipation drug, measurably slowed kidney function decline compared to placebo in 150 patients.
- The mechanism is surprisingly elegant: the drug stimulates spermidine production, which feeds beneficial gut bacteria and energizes mitochondria — the cellular engines that protect kidney tissue.
- This discovery challenges the dominant logic of kidney treatment, shifting focus from filtering out toxins to nurturing the gut-kidney axis and cellular energy systems.
- Researchers are now preparing a larger Phase 3 trial and hunting for biomarkers that could match the right patients to the right treatment, pushing toward genuinely personalized kidney care.
A team at Tohoku University began with a simple observation: constipation and kidney decline tend to travel together. Professor Takaaki Abe and his colleagues wondered whether that relationship was merely coincidental, or whether disruption of the gut's bacterial ecosystem was actively worsening kidney function. If the chain held, treating the constipation might protect the kidneys.
To find out, they ran a multicenter Phase II trial enrolling 150 patients with moderate chronic kidney disease across nine Japanese medical centers. Half received lubiprostone — a drug that stimulates bowel movement — while the other half received a placebo. The results were meaningful: those on lubiprostone showed a slower decline in estimated glomerular filtration rate, the standard measure of how well kidneys are performing.
The mechanism behind the improvement proved to be the most compelling part of the story. Lubiprostone increased production of spermidine, a compound that promotes beneficial gut bacteria and enhances mitochondrial function. Better-energized mitochondria, in turn, helped shield kidney cells from further damage — a chain of causation running from bowel to microbiome to cellular powerhouse to organ.
What distinguishes this finding is not just the unexpected source of the benefit, but the therapeutic logic it represents. Where current kidney treatments focus on clearing uremic toxins from the blood, this approach works upstream — through the gut-kidney axis and cellular energy production. The researchers, whose work appears in Science Advances, now plan a Phase 3 trial and hope to identify biomarkers for personalized treatment.
The implications reach further still. If a constipation drug can restore mitochondrial vitality in kidney patients, the same principle may hold for other diseases rooted in cellular energy failure. For now, it offers something that has long been absent from chronic kidney disease: a credible reason for hope.
Researchers in Japan have stumbled onto an unexpected path forward in treating chronic kidney disease: a medication designed to relieve constipation. The discovery emerged from a simple observation—that constipation frequently accompanies kidney decline—and led a team at Tohoku University to ask whether treating one might help the other.
ChronicKidney disease affects millions of people worldwide and typically progresses relentlessly toward dialysis dependence. Despite its prevalence and severity, no approved drugs exist that can actually restore lost kidney function. The condition remains largely managed through symptom control and, eventually, mechanical filtration of the blood. This absence of restorative options is what makes the new findings significant.
Professor Takaaki Abe and his colleagues reasoned that constipation disrupts the bacterial ecosystem of the gut, which in turn worsens kidney function. If that chain of causation held, they hypothesized, then fixing the constipation might improve kidney health. To test this theory, they organized a multicenter Phase II trial across nine Japanese medical centers, enrolling 150 patients with moderate chronic kidney disease. Half received lubiprostone—a drug that stimulates bowel movement—at doses of either 8 or 16 micrograms, while the other half received placebo.
The results justified the gamble. Patients who took lubiprostone experienced a slower decline in kidney function compared to those on placebo, measured by the estimated glomerular filtration rate, the standard clinical metric for kidney performance. The mechanism turned out to be elegant: the drug boosted production of spermidine, a compound that enhances mitochondrial activity by promoting the growth of beneficial bacteria in the gut. Better-functioning mitochondria in turn protected the kidneys from further damage.
What makes this finding remarkable is not just that a constipation medication helps kidneys, but that it points toward an entirely different therapeutic strategy for kidney disease. Current treatments focus on reducing uremic toxins—the waste products that accumulate when kidneys fail. This approach targets the gut-kidney axis instead, working through the microbiota and cellular energy production. The researchers now plan to launch a larger Phase 3 trial and to identify biomarkers that could predict which patients will benefit most from the treatment. Their ultimate goal is personalized medicine for kidney disease, tailored to each patient's biology rather than applied as a one-size-fits-all intervention.
The work, published in Science Advances, opens a door that extends beyond kidney disease alone. If constipation medication can improve mitochondrial function in kidney patients, the same principle might apply to other conditions rooted in cellular energy failure. For the millions of people living with chronic kidney disease, the finding offers something that has been scarce: genuine hope for slowing a disease that has long seemed inevitable in its progression.
Notable Quotes
Constipation disrupts the intestinal microbiota, which worsens kidney function. By treating constipation, we could improve kidney function.— Professor Takaaki Abe, Tohoku University Graduate School of Medicine
The Hearth Conversation Another angle on the story
Why would constipation and kidney disease be connected at all? They seem like separate systems.
They're not as separate as they seem. The gut microbiota—the bacteria living in your intestines—influences kidney health through several pathways. When constipation disrupts that bacterial balance, it cascades into kidney damage. The researchers essentially reversed the problem.
And lubiprostone just happens to work because it treats constipation?
Not just because of that. The drug triggers a specific chain: it promotes bacteria that produce spermidine, which energizes the mitochondria—the powerhouses of cells. Better mitochondrial function means the kidneys can resist damage more effectively.
So this isn't a kidney drug at all. It's a gut drug that happens to help kidneys.
Exactly. That's what makes it so interesting. It suggests we've been looking at kidney disease too narrowly, focusing only on the kidneys themselves. The real leverage point might be upstream, in the gut.
Will this work for everyone with kidney disease?
That's the next question. They're planning Phase 3 trials to find biomarkers—biological signatures that predict who will respond. Not every patient may benefit equally.
What happens if this works at scale?
It could transform how we think about treating kidney disease. Instead of just managing symptoms until dialysis, we might actually slow or halt progression. And the same principle could apply to other diseases involving mitochondrial dysfunction.